NewAmsterdam Pharma Company N.V.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-203.8M | $-241.6M | $-176.9M | $-22.6M | $-41.8M |
| Depreciation & Amortization | $220.0K | $113.0K | $49.0K | $9.0K | $5.0K |
| Depreciation | — | — | — | — | — |
| Amortization | — | — | — | — | — |
| Stock-Based Compensation | $59.4M | $33.6M | $24.6M | $4.1M | $1.2M |
| Net Cash from Operating Activities | $-147.8M | $-158.6M | $-141.2M | $10.7M | $-29.5M |
| Investing Activities | |||||
| Capital Expenditures | $246.0K | $672.0K | $24.0K | $221.0K | $24.0K |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | $-174.9M | $-62.8M | $-24.0K | $-221.0K | $-24.0K |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — |
| Net Cash from Financing Activities | $29.5M | $659.5M | $8.9M | $391.9M | $84.7M |
| Net Change in Cash | — | — | — | — | — |
| Free Cash Flow | $-148.0M | $-159.2M | $-141.2M | $10.4M | $-29.5M |